Aktis Oncology, Inc. (AKTS) Q1 2026 Earnings
AKTS·Reported May 11, 2026·Before market open
Aktis Oncology, Inc. reported Q1 2026 revenue of $3.2M, beat analyst consensus of $2.2M by $997.0K. Diluted EPS came in at $-0.38, missed the $-0.31 consensus by $0.07.
Revenue
$3.2Mbeat by $997.0K
Consensus: $2.2MDiluted EPS
$-0.38missed by $0.07
Consensus: $-0.31
SEC Filings
Earnings release8-K not filed yet
Quarterly report10-Q / 10-K not filed yet
Filings will appear here once submitted to SEC EDGAR.
Q1 2026 Earnings FAQ
Common questions about Aktis Oncology, Inc. 's Q1 2026 earnings report.
Aktis Oncology, Inc. (AKTS) reported Q1 2026 earnings on May 11, 2026 before market open.
Aktis Oncology, Inc. reported revenue of $3.2M and diluted EPS of $-0.38 for Q1 2026.
Revenue beat the consensus estimate of $2.2M by $997.0K. EPS missed the consensus estimate of $-0.31 by $0.07.